Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute...

Area of Science:

• Cardiology
• Pharmacology

Background:

• Acute myocardial infarction (MI) with ST elevation or new left bundle branch block requires timely intervention.
• Glycoprotein IIb/IIIa receptor antagonists are crucial adjunctive therapies during primary percutaneous coronary intervention (PCI).
• Eptifibatide and abciximab are commonly used agents, but direct comparative outcome data are important.

Purpose of the Study:

• To compare the clinical outcomes of patients undergoing primary PCI for acute MI who received either eptifibatide or abciximab.
• To assess in-hospital and 1-year follow-up adverse events associated with each glycoprotein IIb/IIIa receptor antagonist.

Main Methods:

• An observational analysis of 576 patients undergoing primary PCI for acute MI between 1999 and 2004.
• Propensity score adjustment was used to control for baseline differences between the eptifibatide and abciximab groups.
• Logistic regression and Cox proportional hazards models analyzed the association between antagonist choice and adverse events.

Main Results:

• In-hospital death or MI rates were similar: 6% for eptifibatide vs. 5% for abciximab (P = .95).
• Adjusted analysis confirmed no significant difference in in-hospital adverse events (adjusted odds ratio, 1.03; P = .95).
• At 1-year follow-up, composite endpoint rates (death, MI, target vessel revascularization) were comparable: 20.9% for eptifibatide vs. 22.3% for abciximab (adjusted hazard ratio, 1.36; P = -.16).

Conclusions:

• In this observational study, eptifibatide and abciximab demonstrated similar clinical outcomes for patients undergoing primary PCI for acute MI.
• The findings suggest comparable efficacy and safety profiles for both agents in this patient population.
• Further comparative research is recommended to validate these findings.